Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review
Open accessThe DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognosis, specifically the case fatality and duration, of untreated tuberculosis is important as many patients are not correctly diagnosed and therefore receive inadequate or no treatment. Furthermore, duration and case fatality of tuberculosis are key parameters in interpreting epidemiological data. METHODOLOGY AND PRINCIPAL FINDINGS: To estimate the duration and case fatality of untreated pulmonary tuberculosis in HIV negative patients we reviewed studies from the pre-chemotherapy era. Untreated smear-positive tuberculosis among HIV negative individuals has a 10-year case fatality variously reported between 53% and 86%, with a weighted mean of 70%. Ten-year case fatality of culture-positive smear-negative tuberculosis was nowhere reported directly but can be indirectly estimated to be approximately 20%. The duration of tuberculosis from onset to cure or death is approximately 3 years and appears to be similar for smear-positive and smear-negative tuberculosis. CONCLUSIONS: Current models of untreated tuberculosis that assume a total duration of 2 years until self-cure or death underestimate the duration of disease by about one year, but their case fatality estimates of 70% for smear-positive and 20% for culture-positive smear-negative tuberculosis appear to be satisfactory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Selection of papers. Flowchart schematically showing inclusion and exclusion of papers. Those marked with a * were excluded either because they were referred to at places in the text that did not discuss duration of tuberculosis, tuberculosis mortality, case fatality, life tables or natural history, or because the title indicated that the paper was not about one of these topics; ** for two of these, data were included to the extent mentioned by Berg [115] (see legend of Table 3).](https://figures.cochat.ai/paper-figures/8114c3bf70fd484d9fe91b2b4854751c/natural-history-of-tuberculosis-duration-and-fatality-of-untreated-pulmonary-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the average duration until cure or death is 3 years for untreated patients with tuberculosis,25”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553 · cited 2×
“a 70% CF, as used by WHO and others in their estimates of the burden of tuberculosis [27], seems a reasonable ballpark figure.”
BackgroundMethodSelf-citationTuberculosis and diabetes mellitus: convergence of two epidemics
Dooley, K. E., & Chaisson, R. E. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70282-8 · Cited by 932 · cited 1×
“tuberculosis and progression to tuberculosis disease is influenced by host factors and especially risk of progression depends on the hosts’ immune status, which may be reduced due to concomitant HIV infection, diabetes, and other underlying diseases [27,28].”
BackgroundFluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review
Steingart, K. R., Henry, M., Ng, V., Hopewell, P. C., Ramsay, A., Cunningham, J., Urbanczik, R., Perkins, M., Aziz, M. A., & Pai, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70578-3 · Cited by 798 · cited 1×
“smear, with low sensitivity for paucibacillary disease, is the only available diagnostic tool [6].”
BackgroundThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“Furthermore, Mycobacterium tuberculosis strains resistant to rifampicin and INH might be less fit than drug susceptible strains and therefore lead to longer duration of disease with less mortality [15].”
BackgroundDye, C. (2005) · JAMA · doi:10.1001/jama.293.22.2767 · Cited by 534 · cited 1×
“course) strategy only offer free treatment to smear-positive cases in view of their disproportionate role in tuberculosis transmission and thus their large public health impact [7].”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 1×
“The prognosis of untreated tuberculosis is difficult to study these days as leaving patients untreated, especially in a study setting, is unethical. As an alternative, one could consider, as an approximation, the prognosis of multi-drug resistant (MDR) tuberculosis treated with first line drugs. However, MDR-tuberculo…”
HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm
Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518665 · Cited by 483 · cited 4×
“As regards CF, the review of Payne and Bellamy [143] provided no information on the prognosis of HIV positive MDR-tuberculosis patients.”
BackgroundInfluentialTreatment of Tuberculosis in Patients with Advanced Human Immunodeficiency Virus Infection
Small, P. M., Schecter, G. F., Goodman, P. C., Sande, M. A., Chaisson, R. E., & Hopewell, P. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101313240503 · Cited by 477 · cited 1×
“tuberculosis, of 16 months [145].”
The White Plague: Tuberculosis, Man and Society
(1954) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1954.tb85837.x · Cited by 388
Recurrence in tuberculosis: relapse or reinfection?
Lambert, M.-L., Hasker, E., Deun, A. V., Roberfroid, D., Boelaert, M., & Van der Stuyft, P. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00607-8 · Cited by 225 · cited 1×
“Moreover, of the two possible end points, cure is hard to measure, as relapses are common [140] and establishing cure in untreated tuberculosis patients requires extensive medical investigations.”
Background
Research works printed but not linked: 27
- Rutledge JA Crouch JB 1919 The ultimate results in 1654 cases of tuberculosis treated at the modern Woodmen of America sanatorium. Am Rev Tuberc 2 755 763
- Loewenstein E 1931 Die Zuchtung der Tuberkelbazillen aus dem stroemenden Blute. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg 1 127
- Jensen KA 1932 Reinzuchtung und Typenbestimmung von Tuberkelbazillenstammen. Zentralb Bakteriol Parasitenkd Infektionskr Hyg Abt 1 222
- Hamel GH 1928 Jahresversammlung des Deutschen Zentral-komitees zur Bekämpfung der Tuberkulose. Erster Verhandlungstag. (discussions during annual meeting of the German Tuberculosis Control Committee). Zeitschr Tuberk 51 497 531
- Meidell B 1931 Die wahrscheinliche Lebensdauer und die Sterblichkeitsmessung. Skandinavisk aktuarietidskrift 14 217 230
- Anonymous 1936 The expectation of life of the tuberculous. Tubercle 17 171 172
- Oldenburg F Seïsoff C 1931 Gedanken über das Schicksal offentuberkulöser Eisenbahner auf Grund statistischer Erhebungen. Zeitschr Tuberk 61 334 349
- Phillips S 1964 Relapse in treated cases of pulmonary tuberculosis. II. Six-year follow-up of 109 patients discharged from the hospital with medical approval, 1955-1956. Am Rev Respir Dis 90 61 66 14178627
- May W 1928 Welche Konsequenzen ergeben sich aus der Dauerstatistik der Heilverfahren bei Offentuberkulösen? Zeitschr Tuberk 51 177 184
- Ruge H 1909 Dauererfolge nach 10 Jahren bei Lungetuberkulose im Hochgebirge. Zeitsch Tuberk 15 146 168
- Saegler E 1934 Beitrag zur Frage der Beziehungen zwischen Tuberkulose und Lebensalter. Zeitschr Tuberk 71 285 288
- Stadler E 1903 Der Einfluss der Lungetuberkulose of Lebensdauer und Erwerbsfähigkeit und der Werth der Volksheilstättenbehandlung. Deutsch Arch Klin Med 95 412 440
- Stephens MG 1941 Follow-up of 1041 tuberculous patients. Am Rev Tuberc 44 451 462
- Holst PF Nicolaysen L Ustvedt Y 1906 Untersuchungen über die Lebensdauer der Schwindsüchtigen in Norwegen. Deutsch Arch Klin Med 88 325 350
- Braeuning H 1920 Tuberkulöse Erkrankungen bei Schwestern infolge von Ansteckung im Dienst und ihre Verhütung. Zeitschr Tuberk 33 129 136
- De Besche AD Jørgenson JO 1925 Dødeligheten av Lungentuberkulose i Oslo blandt til Byen indflyttede og der fødte Individer. Norsk Magazin for Laegevidenskaben 86 1229 1253
- Hamel GH 1912 Tuberkulosearbeiten aus dem Kaiserlichen Gesundheitsamte. Deutsche Heilstätten für Lungenkranke. Geschichtliche und statistische Mitteilungen V. 13. Heft. Berlin, Germany Springer Verlag 124
- Van Joost CRNF 1935 Opmerkingen naar aanleiding van een 200 tal met kunstmatige pneumothorax- en een 50 tal met middenrifsverlamming (phrenicusexairesis) behandelde gevallen van longtuberculose. Geneeskund Tijdschr v Ned Indië 75 1223 1235
- Van Vliet B 1963 Analyse van de sterfte aan longtuberculose te Amsterdam in de jaren 1960 en 1961. Ned Tijdschr Geneesk 107 2180 2181 14094561
- Pamra SP Goyal SS Mathur GP 1973 Changes in prevalence and incidence of pulmonary tuberculosis in Delhi in recent years. Ind J Tuberc 20 57 64
- Sinding-Larsen CMF 1937 On the collapse treatment of pulmonary tuberculosis. A clinical adaption and follow-up examination of the material from Vejlefjord Sanatorium, 1906-1932. Acta Med Scand 91 39 132
- Magnusson S 1938 Über den Verlauf und die Letalität der Tuberkulose in den verschiedenen Altersperioden. Acta Tuberc Scand 12 201 263
- Münchbach W 1933 Das Schicksal des lungentuberkulösen Erwachsenen. Ergibnisse der Heilstattenbehandlung von annähernd 10000 Männern und Frauen. Tuberkulose-Bibliothek 49 64
- Braeuning H Neissen A 1936 Prognose der offenen Tuberkulose, Technik der Prognose-stellung und Rentabilität des Heilverfahrens. Zeitschr Tuberk 75 305 323
- Braeuning H Neissen A 1933 Die Prognose der offenen Lungentuberkulose. Tuberkulose-Bibliothek 52 40
- Griep WA 1939 De prognose van de open longtuberculose. [Thesis] Amsterdam University of Amsterdam 87
- Braeuning H 1930 Über die Letalität, Morbidität und Infektionsdauer der offenen Lungentuberkulose. Zeitschr Tuberk 59 109 111
Cited by
Items 601–630 of 630
(Un)safe Haven in Bangkok : Urban Refugee Protection in a Middle Income Country
Batréau, Q. (2020) · theses.fr (ABES) · doi:10.70675/d45b92f9z7390z4eadzbe60z6dce3d6d369e · Cited by 1
Liu, Y., Xu, X., Mao, C., Wang, B., Cocorullo, M., Tresoldi, A., Mori, M., Wang, B., Lu, Y., Huang, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03770
Santoso, E. L., Ridho, M. R., Iskandar, M., Firstania, V., & Sebastian, P. G. A. A. (2026) · Surabaya Biomedical Journal · doi:10.30649/v5i2.169
Evaluation of tuberculosis surveillance system in Afghanistan: a teaching case-study
Saeed, K. M. I., Naeemi, S., & Hakim, M. S. (2026) · Pan African Medical Journal · doi:10.11604/pamj.supp.2026.53.1.46336
Kowada, A. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-112006
“Utility values for each health state were obtained from published sources 31 32 and discounted at an annual rate of 3% 16 (online supplemental table 1).”
Boucherma, R., Laboratoire des Mathématiques Appliquées et Didactique, E. N. S. D. C., Abdelouahab, M.-S., Berkal, M., Radwan, T., Yildirim, Y., & Ahmed, K. K. (2026) · AIMS Mathematics · doi:10.3934/math.2026550
Sineke, N., Faye, L. M., Dlatu, N., Ombinda-Lemboumba, S. S., & Apalata, T. R. (2026) · Infectious Disease Reports · doi:10.3390/idr18050110
“[19,22] DR-TB excess mortality ( d r ) 0.10 year − 1 A higher excess mortality parameter was assumed for DR-TB to represent its poorer outcomes and greater treatment complexity relative to DS-TB.”
InfluentialAssessing the Impact of Interventions on Tuberculosis Control: India Based Modelling FrameworkPreprint
Raj, Y., Parthasarathy, R., Mitra, M. K., & Mehra, S. (2026) · medRxiv · doi:10.64898/2026.05.20.26353466
SIMULATION OF POLICY LEVERS ACROSS THE TUBERCULOSIS CARE CASCADE
Tampi, R. (2026) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
All hands to the wheel to change course on the strategy for TB control
Marks, G. B. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag299
TB Mukt Bharat: Challenges, Opportunities, and the Road Ahead
Sharma, R. (2026) · Journal of Public and Clinical Health Research · doi:10.63486/jpchr.26071601
Robust AI Framework for Comprehensive Tuberculosis Drug Resistance Profiling with Rapid AdaptabilityPreprint
Liu, C. X., Zhu, H., Wang, X., Li, Y., Wang, H., & Yang, Y. (2026) · medRxiv · doi:10.64898/2026.07.20.26358475
Lake, M. (2024) · Apollo (University of Cambridge) · doi:10.17863/cam.109644
Determinants of tuberculosis treatment success in Semarang City, Indonesia
Fauzi, L., Hardanis, F. N., Anggorowati, L., & Kanthawee, P. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202624702007
Müller, P. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Deciphering the intricacies of immune control
Held, K. (2026) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.37240
Upaya Pencegahan Tuberculosis melalui Edukasi di Puskesmas Ciawigebang Kabupaten Kuningan
Febiyanti, S., Nurlia, R., Azmia, S., Ramdhani, N. L., & Fachrozi, F. N. (2026) · Jurnal Pengabdian Masyarakat (abdira) · doi:10.31004/abdira.v6i3.2235
Tiyou, A., Belina, M., Seid, Y., & Haftu, B. (2026) · Research Square · doi:10.21203/rs.3.rs-10411125/v1
Khoda, P., Prasad, S. N., & Martcheva, M. (2026) · Mathematics and Computers in Simulation · doi:10.1016/j.matcom.2026.08.011
Chu, P.-W., Lo, H.-Y., Chan, P., & Lin, H.-H. (2026) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2026.09.008
Eliciting moral preferences under image concerns: Theory and experiment
Bénabou, R., Falk, A., Henkel, L., & Jean Tirole, Z. (2026) · Games and Economic Behavior · doi:10.1016/j.geb.2026.104044
Biomarker Discovery for Point-of-Care Diagnostics
vonBargen, R. E. U. (2026) · SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)
The regulatory landscape in tuberculosis integrated research platforms
Pereiro, J. E., Saluzzo, F., González-Moreno, J., Cavaleri, M., Hittel, N., Lienhardt, C., Rombouts, K., Simonsson, U., Cirillo, D. M., & Sánchez‐Montalvá, A. (2026) · European Respiratory Journal · doi:10.1183/13993003.00646-2026
Bansal, A., Sharma, D., Yadav, S., Kumar, V., & Sharma, V. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12869-6
“Simultaneously to the development of chemotherapy it was one of the leading causes of death in both the western and a number of non-Western nations [2].”
Interleukin-6 as a potential biomarker in cavitary pulmonary tuberculosis
Yaman, H. I., Ashmawi, S. S., Elmihi, N. M. B., & Abdeldaim, Y. (2026) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.4103/ecdt.ecdt_96_25
BindingDB Entry 50016897: Tuberculosis Drug Discovery: Challenges and New Horizons.
BindingDB (2023) · UC San Diego · doi:10.7270/q2rr238m
Jo, Y., Bloedow, J., Shrestha, S., Wenger, E. A., Bulekova, K., & Chang, S. T. (2026) · medRxiv · doi:10.64898/2026.10.27.26366617
Bagheri, B., Denning, D. W., Botha, A., Ncube, P., & Sampson, S. L. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00195-24
Metadata
- Authors
- Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- GGD Amsterdam (NL)
- Stellenbosch University (ZA)
- United Arab Emirates University (AE)
- Corresponding author
- Tiemersma, Edine W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-04
- Volume
- 6
- Issue
- 4
- Pages
- e17601
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3070694
- OpenAlex
- W2138041013
- Cited by
- 583
- References
- 136
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 46 · 2023: 48 · 2022: 40 · 2021: 36 · 2020: 38 · 2019: 39 · 2018: 43 · 2017: 42 · 2016: 35 · 2015: 43 · 2014: 39 · 2013: 31 · 2012: 10
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- UvA-DARE (University of Amsterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Keywords
- case fatality, disease duration, HIV-negative patients, smear-positive tuberculosis, smear-negative tuberculosis, culture-positive tuberculosis, tuberculosis prognosis
- MeSH terms
- Humans, Time Factors, Tuberculosis, Pulmonary, Survival Analysis, HIV Seronegativity, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.